Breast cancer is the leading cause of death among women worldwide. When breast cancer spreads to other parts of the body, the prognosis is poor. Currently, there is no treatment […]
Among the first-generation ADC drugs, traditional chemotherapy drugs such as methotrexate, vinblastine, and doxorubicin were used as cytotoxic payloads. However, due to insufficient cytotoxicity and selectivity against tumor cells, the first-generation […]
The concept of ADCs was first proposed by Nobel Prize winner Paul Ehrlich in 1913. But it was not until 1975, when hybridoma technology began to be used to produce monoclonal […]
So far, the FDA and EMA have approved six ADC drugs for patients with solid tumors. Fig. 1 depicts the composition of each ADC (targeting antigen, mAb type, payload, and linker), […]
The development of antibody-drug conjugates (ADCs) has progressed significantly over the past decade due to improvements in payloads, linkers, and conjugation methods. In particular, linker design plays a key role […]
The development of antibody-drug conjugates (ADCs) has progressed significantly over the past decade due to improvements in payloads, linkers, and conjugation methods. In particular, linker design plays a key role […]
- 2 of 2
- « Previous
- 1
- 2